BTG3-AS1

Across TCGA pan-cancer cohorts, BTG3-AS1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of BTG3-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where BTG3-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types BTG3-AS1 is over-expressed in tumor, although a few such as KIRC and BRCA show the opposite, repressed pattern.

KIRC, BRCA, and HNSC are the cancer types where BTG3-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTG3-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.734	<.001	12	view →
BRCA	All	III,IV	−0.365	<.001	8	view →
HNSC	All	All	+0.273	.001	8	view →
KIRP	Male	All	−0.625	<.001	7	view →
THCA	All	All	−0.352	.001	7	view →
LUSC	All	All	+0.379	<.001	4	view →
LIHC	All	All	+0.075	<.001	4	view →
CHOL	All	All	+0.288	<.001	3	view →
PRAD	All	All	−0.441	<.001	2	view →
KICH	All	IV	−1.097	.044	1	view →
LUSC	Male	III,IV	−0.365	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 10 lineages.

BTG3-AS1–KIRC

Open the KIRC breakdown →